Biomarkers of HIV related central nervous system disease

References

• Abdulle S, Hagberg L, Gisslen M. Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients. HIV Medicine 2005; 6: 164–169
   PubMed Web of Science ®Google Scholar
• Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslen M. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS 2002; 16: 2145–2149
   PubMed Web of Science ®Google Scholar
• Abdulle S, Mellgren A, Brew BJ, Cinque P, Hagberg L, Price RW, et al. CSF neurofilament protein (NFL)–A marker of active HIV-related neurodegeneration. Journal of Neurology 2007; 254(8)1026–1032
   PubMed Web of Science ®Google Scholar
• Achim CL, Heyes MP, Wiley CA. Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. Journal of Clinical Investigation 1993; 91: 2769–2775
   PubMed Web of Science ®Google Scholar
• Albrecht D, Garcia L, Cartier L, Kettlun AM, Vergara C, Collados L, et al. Trophic factors in cerebrospinal fluid and spinal cord of patients with tropical spastic paraparesis, HIV, and Creutzfeldt-Jakob disease. AIDS Research Hum Retroviruses 2006; 22: 248–254
   PubMedGoogle Scholar
• Andersson LM, Hagberg L, Fuchs D, Svennerholm B, Gisslen M. Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individuals - Correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels. Journal of Neurovirology 2001; 7: 542–547
   PubMed Web of Science ®Google Scholar
• Andreasen N, Sjogren M, Blennow K. CSF markers for Alzheimer's disease: Total tau, phospho-tau and Abeta42. World Journal of Biol Psychiatry 2003; 4: 147–155
   PubMed Web of Science ®Google Scholar
• Armitage RJ. Tumor necrosis factor receptor superfamily members and their ligands. Current Opinion Immunol 1994; 6: 407–413
   PubMed Web of Science ®Google Scholar
• Avison MJ, Nath A, Greene-Avison R, Schmitt FA, Bales RA, Ethisham A, et al. Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. Journal of Neurovirology 2004; 10: 223–232
   PubMed Web of Science ®Google Scholar
• Baker SJ, Reddy EP. Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene 1996; 12: 1–9
   PubMed Web of Science ®Google Scholar
• Bazan NG, Packard MG, Teather L, Allan G. Bioactive lipids in excitatory neurotransmission and neuronal plasticity. Neurochem Int 1997; 30: 225–231
   PubMed Web of Science ®Google Scholar
• Behan WM, McDonald M, Darlington LG, Stone TW. Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: Protection by melatonin and deprenyl. British Journal of Pharmacology 1999; 128: 1754–1760
   PubMed Web of Science ®Google Scholar
• Berger JR, Avison M, Mootoor Y, Beach C. Cerebrospinal fluid proteomics and human immunodeficiency virus dementia: Preliminary observations. Journal of Neurovirology 2005; 11: 557–562
   PubMed Web of Science ®Google Scholar
• Bernasconi S, Cinque P, Peri G, Sozzani S, Crociati A, Torri W, et al. Selective elevation of monocyte chemotactic protein-1 in the cerebrospinal fluid of AIDS patients with cytomegalovirus encephalitis. Journal of Infectious Diseases 1996; 174: 1098–1101
   PubMed Web of Science ®Google Scholar
• Bito H, Nakamura M, Honda Z, Izumi T, Iwatsubo T, Seyama Y, et al. Platelet-activating factor (PAF) receptor in rat brain: PAF mobilizes intracellular Ca2+ in hippocampal neurons. Neuron 1992; 9: 285–294
   PubMed Web of Science ®Google Scholar
• Brew BJ. AIDS dementia complex. HIV neurology, BJ Brew. Oxford University Press, New York 2001a; 53–90
   Google Scholar
• Brew BJ. Principles of HIV Neurology. HIV neurology, BJ Brew. Oxford University Press, New York 2001b; 32–35
   Google Scholar
• Brew BJ, Bhalla RB, Paul M, Gallardo H, McArthur JC, Schwartz MK, et al. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Annals of Neurology 1990; 28: 556–560
   PubMed Web of Science ®Google Scholar
• Brew BJ, Bhalla RB, Paul M, Sidtis JJ, Keilp JJ, Sadler AE, et al. Cerebrospinal fluid beta 2-microglobulin in patients with AIDS dementia complex: An expanded series including response to zidovudine treatment. AIDS 1992; 6: 461–465
   PubMedGoogle Scholar
• Brew BJ, Dunbar N, Pemberton L, Kaldor J. Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. Journal of Infectious Diseases 1996; 174: 294–298
   PubMed Web of Science ®Google Scholar
• Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology 2005; 65: 1490–1492
   PubMed Web of Science ®Google Scholar
• Brew BJ, Pemberton L, Cunningham P, Law MG. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. Journal of Infectious Diseases 1997; 175: 963–966
   PubMed Web of Science ®Google Scholar
• Calvo ME, Arranz GF, Sánchez-Portocarrero J, Roca AV, Puente M, Elias AA, et al. [Alpha tumor necrosis factor in central nervous system disease associated with HIV infection.]. An Med Interna 1995; 12: 263–266
   PubMedGoogle Scholar
• Campbell IL, Krucker T, Steffensen S, Akwa Y, Powell HC, Lane T, et al. Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha. Brain Research 1999; 835: 46–61
   PubMed Web of Science ®Google Scholar
• Cauwels A, Frei K, Sansano S, Fearns C, Ulevitch R, Zimmerli W, et al. The origin and function of soluble CD14 in experimental bacterial meningitis. Journal of Immunology 1999; 162: 4762–4772
   PubMed Web of Science ®Google Scholar
• Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, et al. Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8: 237–249
   PubMed Web of Science ®Google Scholar
• Cherner M, Letendre S, Heaton RK, Durelle J, Marquie-Beck J, Gragg B, et al. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 2005; 64: 1343–1347
   PubMed Web of Science ®Google Scholar
• Cinque P, Bestetti A, Marenzi R, Sala S, Gisslen M, Hagberg L, et al. Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. Journal of Neuroimmunology 2005; 168: 154–163
   PubMed Web of Science ®Google Scholar
• Cinque P, Nebuloni M, Santovito ML, Price RW, Gisslen M, Hagberg L, et al. The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations. Annals of Neurology 2004; 55: 687–694
   PubMed Web of Science ®Google Scholar
• Cinque P, Vago L, Mengozzi M, Torri V, Ceresa D, Vicenzi E, et al. Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS 1998; 12: 1327–1332
   PubMed Web of Science ®Google Scholar
• Conant K, Garzino-Demo A, Nath A, McArthur JC, Halliday W, Power C, et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proceedings of the National Academy of Science of the USA 1998; 95: 3117–3121
   PubMed Web of Science ®Google Scholar
• Conant K, McArthur JC, Griffin DE, Sjulson L, Wahl LM, Irani DN. Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia. Annals of Neurology 1999; 46: 391–398
   PubMed Web of Science ®Google Scholar
• Cosman D. Hematopoietic cell growth factors and their receptors. Blood cell biochemistry, Vol 7, AD Whetten, J Gordon. Plenum Press, New York 1996
   Google Scholar
• Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 2006; 66: 1447–1450
   PubMed Web of Science ®Google Scholar
• Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 2003; 17: 1539–1545
   PubMed Web of Science ®Google Scholar
• Ellis RJ, Gamst AC, Capparelli E, Spector SA, Hsia K, Wolfson T, et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 2000; 54: 927–936
   PubMed Web of Science ®Google Scholar
• Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. Annals of Neurology 1997; 42: 679–688
   PubMed Web of Science ®Google Scholar
• Ellis RJ, Moore DJ, Childers ME, Letendre S, McCutchan JA, Wolfson T, et al. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol 2002; 59: 923–928
   PubMedGoogle Scholar
• Elovaara I, Iivanainen M, Valle SL, Suni J, Tervo T, Lahdevirta J. CSF protein and cellular profiles in various stages of HIV infection related to neurological manifestations. Journal of Neurological Science 1987; 78: 331–342
   PubMedGoogle Scholar
• Enting RH, Foudraine NA, Lange JM, Jurriaans S, van der Poll T, Weverling GJ, et al. Cerebrospinal fluid beta2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine. Journal of Neuroimmunology 2000; 102: 216–221
   PubMedGoogle Scholar
• Epstein LG, Gelbard HA. HIV-1-induced neuronal injury in the developing brain. Journal of Leukoc Biol 1999; 65: 453–457
   PubMed Web of Science ®Google Scholar
• Erichsen D, Lopez AL, Peng H, Niemann D, Williams C, Bauer M, et al. Neuronal injury regulates fractalkine: Relevance for HIV-1 associated dementia. Journal of Neuroimmunology 2003; 138: 144–155
   PubMed Web of Science ®Google Scholar
• Franciotta DM, Melzi d’Eril GL, Bono G, Brustia R, Ruberto G, Pagani I. Tumor necrosis factor alpha levels in serum and cerebrospinal fluid of patients with AIDS. Funct Neurol 1992; 7: 35–38
   PubMedGoogle Scholar
• Franconi F, Miceli M, De Montis MG, Crisafi EL, Bennardini F, Tagliamonte A. NMDA receptors play an anti-aggregating role in human platelets. Thromb Haemost 1996; 76: 84–87
   PubMed Web of Science ®Google Scholar
• Fuchs D, Forsman A, Hagberg L, Larsson M, Norkrans G, Reibnegger G, et al. Immune activation and decreased tryptophan in patients with HIV-1 infection. Journal of Interferon Research 1990; 10: 599–603
   PubMedGoogle Scholar
• Gallo P, Frei K, Rordorf C, Lazdins J, Tavolato B, Fontana A. Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system: An evaluation of cytokines in cerebrospinal fluid. Journal of Neuroimmunology 1989a; 23: 109–116
   PubMed Web of Science ®Google Scholar
• Gallo P, Laverda AM, De Rossi A, Pagni S, Del, Mistro A, Cogo P, et al. Immunological markers in the cerebrospinal fluid of HIV-1-infected children. Acta Paediatr Scand 1991; 80: 659–666
   PubMed Web of Science ®Google Scholar
• Gallo P, Piccinno MG, Pagni S, Argentiero V, Giometto B, Bozza F, et al. Immune activation in multiple sclerosis: Study of IL-2, sIL-2R, and gamma-IFN levels in serum and cerebrospinal fluid. Journal of Neurological Science 1989b; 92: 9–15
   PubMed Web of Science ®Google Scholar
• Gallo P, Sivieri S, Rinaldi L, Yan XB, Lolli F, De Rossi A, et al. Intrathecal synthesis of interleukin-10 (IL-10) in viral and inflammatory diseases of the central nervous system. Journal of Neurological Science 1994; 126: 49–53
   PubMed Web of Science ®Google Scholar
• Gelbard HA, Nottet HS, Swindells S, Jett M, Dzenko KA, Genis P, et al. Platelet-activating factor: A candidate human immunodeficiency virus type 1-induced neurotoxin. Journal of Virology 1994; 68: 4628–4635
   PubMed Web of Science ®Google Scholar
• Gendelman HE, Zheng J, Coulter CL, Ghorpade A, Che M, Thylin M, et al. Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. Journal of Infectious Diseases 1998; 178: 1000–1007
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Heales SJ, Silver NC, O’Riordan J, Miller RF, Land JM, et al. Raised serum nitrate and nitrite levels in patients with multiple sclerosis. Journal of Neurological Science 1997; 145: 77–81
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Miller RF, Heales SJ, Land JM, Harrison MJ, Thompson EJ. Elevated cerebrospinal fluid and serum nitrate and nitrite levels in patients with central nervous system complications of HIV-1 infection: A correlation with blood-brain-barrier dysfunction. Journal of Neurological Science 1998; 156: 53–58
   PubMed Web of Science ®Google Scholar
• Gisolf EH, van Praag RM, Jurriaans S, Portegies P, Goudsmit J, Danner SA, et al. Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. Journal of Acquired Immune Deficiency Syndrome 2000; 25: 426–433
   PubMed Web of Science ®Google Scholar
• Gisslen M, Hagberg L, Rosengren L, Brew BJ, Cinque P, Spudich S, et al. Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: A combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacology 2007; 2(1)112–119
   PubMed Web of Science ®Google Scholar
• Gisslen M, Rosengren L, Hagberg L, Deeks SG, Price RW. Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection. AIDS Research Therapy 2005; 2: 6
   PubMedGoogle Scholar
• Glass JD, Fedor H, Wesselingh SL, McArthur JC. Immunocytochemical quantitation of human immunodeficiency virus in the brain: Correlations with dementia. Annals of Neurology 1995; 38: 755–762
   PubMed Web of Science ®Google Scholar
• Gonzalez E, Rovin BH, Sen L, Cooke G, Dhanda R, Mummidi S, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proceedings of the National Academy of Science of the USA 2002; 99: 13795–13800
   PubMed Web of Science ®Google Scholar
• Griffin DE, McArthur JC, Cornblath DR. Soluble interleukin-2 receptor and soluble CD8 in serum and cerebrospinal fluid during human immunodeficiency virus-associated neurologic disease. Journal of Neuroimmunology 1990; 28: 97–109
   PubMedGoogle Scholar
• Griffin DE, McArthur JC, Cornblath DR. Neopterin and interferon-gamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease. Neurology 1991; 41: 69–74
   PubMed Web of Science ®Google Scholar
• Griffin DE, Wesselingh SL, McArthur JC. Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia. Annals of Neurology 1994; 35: 592–597
   PubMed Web of Science ®Google Scholar
• Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: Involvement in the pathology of malignant lymphomas. Blood 1995; 85: 3378–3404
   PubMed Web of Science ®Google Scholar
• Hall CD, Snyder CR, Robertson KR, Messenheimer JA, Wilkins JW, Robertson WT, et al. Cerebrospinal fluid analysis in human immunodeficiency virus infection. Ann Clin Lab Sci 1992; 22: 139–143
   PubMed Web of Science ®Google Scholar
• Hamerlinck FF. Neopterin: A review. Exp Dermatol 1999; 8: 167–176
   PubMed Web of Science ®Google Scholar
• He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997; 385: 645–649
   PubMed Web of Science ®Google Scholar
• Heidenreich F, Arendt G, Jander S, Jablonowski H, Stoll G. Serum and cerebrospinal fluid levels of soluble intercellular adhesion molecule 1 (sICAM-1) in patients with HIV-1 associated neurological diseases. Journal of Neuroimmunology 1994; 52: 117–126
   PubMed Web of Science ®Google Scholar
• Hesselgesser J, Horuk R. Chemokine and chemokine receptor expression in the central nervous system. Journal of Neurovirology 1999; 5: 13–26
   PubMed Web of Science ®Google Scholar
• Heyes MP, Brew B, Martin A, Markey SP, Price RW, Bhalla RB, et al. Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome. Adv Exp Med Biol 1991; 294: 687–690
   PubMedGoogle Scholar
• Hu J, Ferreira A, Van Eldik LJ. S100beta induces neuronal cell death through nitric oxide release from astrocytes. Journal of Neurochemistry 1997; 69: 2294–2301
   PubMed Web of Science ®Google Scholar
• Huang SH, Jong AY. Cellular mechanisms of microbial proteins contributing to invasion of the blood-brain barrier. Cell Microbiology 2001; 3: 277–287
   PubMed Web of Science ®Google Scholar
• Johnson MD, Kim P, Tourtellotte W, Federspiel CF. Transforming growth factor beta and monocyte chemotactic protein-1 are elevated in cerebrospinal fluid of immunocompromised patients with HIV-1 infection. Journal of Neuro AIDS 2004; 2: 33–43
   PubMedGoogle Scholar
• Kelder W, McArthur JC, Nance-Sproson T, McClernon D, Griffin DE. Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Annals of Neurology 1998; 44: 831–835
   PubMed Web of Science ®Google Scholar
• Kolb SA, Sporer B, Lahrtz F, Koedel U, Pfister HW, Fontana A. Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV-1-infected individuals as interferon-gamma inducible protein 10. Journal of Neuroimmunology 1999; 93: 172–181
   PubMed Web of Science ®Google Scholar
• Krivine A, Force G, Servan J, Cabee A, Rozenberg F, Dighiero L, et al. Measuring HIV-1 RNA and interferon-alpha in the cerebrospinal fluid of AIDS patients: Insights into the pathogenesis of AIDS Dementia Complex. Journal of Neurovirology 1999; 5: 500–506
   PubMed Web of Science ®Google Scholar
• Kusdra L, McGuire D, Pulliam L. Changes in monocyte/macrophage neurotoxicity in the era of HAART: Implications for HIV-associated dementia. AIDS 2002; 16: 31–38
   PubMed Web of Science ®Google Scholar
• Lafeuillade A, Poggi C, Pellegrino P, Corti K, Profizi N, Sayada C. HIV-1 replication in the plasma and cerebrospinal fluid. Infection 1996; 24: 367–371
   PubMed Web of Science ®Google Scholar
• Landmann R, Muller B, Zimmerli W. CD14, new aspects of ligand and signal diversity. Microbes Infect 2000; 2: 295–304
   PubMed Web of Science ®Google Scholar
• Laverda AM, Gallo P, De Rossi A, Sivieri S, Cogo P, Pagliaro A, et al. Cerebrospinal fluid analysis in HIV-1-infected children: Immunological and virological findings before and after AZT therapy. Acta Paediatr 1994; 83: 1038–1042
   PubMed Web of Science ®Google Scholar
• Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al. Validation of the CNS penetration-effectiveness rank for qualifying antiretroviral penetration into the central nervous system. Archives of Neurology, for the CHARTER Group. (In press)
   Google Scholar
• Letendre S, Buzzell M, Marquie-Beck J, Cherner M, Ances B, & Ellis RJ. ATH Group. 2006, The effects of antiretroviral use on cerebrospinal fluid biomarkers and neuropsychological performance. In 13th Conference on Retroviruses and Opportunistic Infections: Denver, CO. Available at: www.retroconference.org/2008/
   Google Scholar
• Letendre S, Zheng J, Yiannoutsos C, Lopez A, Ellis R, Marquie-Beck J. Chemokines correlate with cerebral metabolites on magnetic resonance spectroscopy: A sub-study of ACTG 301 and 700. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2004, www.retroconference.org/2008/
   Google Scholar
• Letendre SL, Cherner M, Ellis RJ, Marquie-Beck J, Gragg B, Marcotte T, et al. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: Biological correlates of disease. AIDS 2005; 19(Suppl 3)S72–78
   PubMed Web of Science ®Google Scholar
• Letendre SL, Lanier ER, McCutchan JA. Cerebrospinal fluid beta chemokine concentrations in neurocognitively impaired individuals infected with human immunodeficiency virus type 1. Journal of Infectious Diseases 1999; 180: 310–319
   PubMed Web of Science ®Google Scholar
• Lien E, Aukrust P, Sundan A, Muller F, Froland SS, Espevik T. Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: Correlation to disease progression and clinical events. Blood 1998; 92: 2084–2092
   PubMed Web of Science ®Google Scholar
• Liuzzi GM, Mastroianni CM, Santacroce MP, Fanelli M, D’Agostino C, Vullo V, et al. Increased activity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV-associated neurological diseases. Journal of Neurovirology 2000; 6: 156–163
   PubMed Web of Science ®Google Scholar
• Lotz M, Terkeltaub R, Villiger PM. Cartilage and joint inflammation. Regulation of IL-8 expression by human articular chondrocytes. Journal of Immunology 1992; 148: 466–473
   PubMed Web of Science ®Google Scholar
• Luo X, Carlson KA, Wojna V, Mayo R, Biskup TM, Stoner J, et al. Macrophage proteomic fingerprinting predicts HIV-1-associated cognitive impairment. Neurology 2003; 60: 1931–1937
   PubMed Web of Science ®Google Scholar
• Marshall DW, Brey RL, Butzin CA, Lucey DR, Abbadessa SM, Boswell RN. CSF changes in a longitudinal study of 124 neurologically normal HIV-1-infected US Air Force personnel. Journal of Acquired Immune Deficiency Syndrome 1991; 4: 777–781
   PubMed Web of Science ®Google Scholar
• Marshall DW, Brey RL, Cahill WT, Houk RW, Zajac RA, Boswell RN. Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection. Arch Neurol 1988; 45: 954–958
   PubMedGoogle Scholar
• Martin A, Heyes MP, Salazar AM, Kampen DL, Williams J, Law WA, et al. Progressive slowing of reaction time and increasing cerebrospinal fluid concentrations of quinolinic acid in HIV-infected individuals. Journal of Neuropsychiatry Clin Neurosci 1992; 4: 270–279
   PubMed Web of Science ®Google Scholar
• Mastroianni CM, Paoletti F, Massetti AP, Falciano M, Vullo V. Elevated levels of tumor necrosis factor (TNF) in the cerebrospinal fluid from patients with HIV-associated neurological disorders. Acta Neurologica (Napoli) 1990; 12: 66–67
   PubMedGoogle Scholar
• Mastroianni CM, Paoletti F, Valenti C, Vullo V, Jirillo E, Delia S. Tumour necrosis factor (TNF-alpha) and neurological disorders in HIV infection. Journal of Neurol Neurosurg Psychiatry 1992; 55: 219–221
   PubMed Web of Science ®Google Scholar
• McArthur JC, McClernon DR, Cronin MF, Nance-Sproson TE, Saah AJ, St Clair M, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Annals of Neurology 1997; 42: 689–698
   PubMed Web of Science ®Google Scholar
• McArthur JC, Nance-Sproson TE, Griffin DE, Hoover D, Selnes OA, Miller EN, et al. The diagnostic utility of elevation in cerebrospinal fluid beta 2-microglobulin in HIV-1 dementia. Multicenter AIDS Cohort Study. Neurology 1992; 42: 1707–1712
   PubMed Web of Science ®Google Scholar
• Milstien S, Sakai N, Brew BJ, Krieger C, Vickers JH, Saito K, et al. Cerebrospinal fluid nitrite/nitrate levels in neurologic diseases. Journal of Neurochemistry 1994; 63: 1178–1180
   PubMed Web of Science ®Google Scholar
• Monteiro de Almeida S, Letendre S, Zimmerman J, Lazzaretto D, McCutchan A, Ellis R. Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. Journal of Neuroimmunology 2005; 169: 144–152
   PubMed Web of Science ®Google Scholar
• Neuenburg JK, Furlan S, Bacchetti P, Price RW, Grant RM. Enrichment of activated monocytes in cerebrospinal fluid during antiretroviral therapy. AIDS 2005; 19: 1351–1359
   Google Scholar
• Nockher WA, Bergmann L, Scherberich JE. Increased soluble CD14 serum levels and altered CD14 expression of peripheral blood monocytes in HIV-infected patients. Clin Exp Immunol 1994; 98: 369–374
   PubMed Web of Science ®Google Scholar
• Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Research 2003; 987: 25–31
   PubMed Web of Science ®Google Scholar
• Oppenheim JJ, Ruscetti FW. Cytokines. Medical immunology, TG Parslow, DP Stites, AI Terr, JB Imboden. Lange Medical Books/McGraw-Hill Medical Publishing, New York 2001
   Google Scholar
• Pemberton LA, Brew BJ. Cerebrospinal fluid S-100beta and its relationship with AIDS dementia complex. Journal of Clinical Virology 2001; 22: 249–253
   PubMed Web of Science ®Google Scholar
• Perrella O, Carreiri PB, Perrella A, Sbreglia C, Gorga F, Guarnaccia D, et al. Transforming growth factor beta-1 and interferon-alpha in the AIDS dementia complex (ADC): Possible relationship with cerebral viral load?. European Cytokine Network 2001; 12: 51–55
   PubMed Web of Science ®Google Scholar
• Perrella O, Carrieri PB, Guarnaccia D, Soscia M. Cerebrospinal fluid cytokines in AIDS dementia complex. Journal of Neurology 1992; 239: 387–388
   PubMed Web of Science ®Google Scholar
• Petzold A, Hinds N, Murray NM, Hirsch NP, Grant D, Keir G, et al. CSF neurofilament levels: A potential prognostic marker in Guillain-Barre syndrome. Neurology 2006; 67: 1071–1073
   PubMed Web of Science ®Google Scholar
• Portegies P, Godfried MH, Hintzen RQ, Stam J, van der Poll T, Bakker M, et al. Low levels of specific T cell activation marker CD27 accompanied by elevated levels of markers for non-specific immune activation in the cerebrospinal fluid of patients with AIDS dementia complex. Journal of Neuroimmunology 1993; 48: 241–247
   PubMed Web of Science ®Google Scholar
• Pulliam L, Gascon R, Stubblebine M, McGuire D, McGrath MS. Unique monocyte subset in patients with AIDS dementia. Lancet 1997; 349: 692–695
   PubMed Web of Science ®Google Scholar
• Re DB, Przedborski S. Fractalkine: Moving from chemotaxis to neuroprotection. Nat Neurosci 2006; 9: 859–861
   PubMed Web of Science ®Google Scholar
• Rho MB, Wesselingh S, Glass JD, McArthur JC, Choi S, Griffin J, et al. A potential role for interferon-alpha in the pathogenesis of HIV-associated dementia. Brain Behav Immun 1995; 9: 366–377
   PubMed Web of Science ®Google Scholar
• Rieckmann P, Albrecht M, Ehrenreich H, Weber T, Michel U. Semi-quantitative analysis of cytokine gene expression in blood and cerebrospinal fluid cells by reverse transcriptase polymerase chain reaction. Res Exp Med (Berl) 1995; 195: 17–29
   PubMedGoogle Scholar
• Rieckmann P, Nunke K, Burchhardt M, Albrecht M, Wiltfang J, Ulrich M, et al. Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: An indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier. Journal of Neuroimmunology 1993; 47: 133–140
   PubMed Web of Science ®Google Scholar
• Riedel DJ, Pardo CA, McArthur J, Nath A. Therapy insight: CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome. Nat Clin Pract Neurol 2006; 2: 557–565
   PubMedGoogle Scholar
• Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia 2002; 39: 279–291
   PubMed Web of Science ®Google Scholar
• Ryan LA, Zheng J, Brester M, Bohac D, Hahn F, Anderson J, et al. Plasma levels of soluble CD14 and tumor necrosis factor-alpha type II receptor correlate with cognitive dysfunction during human immunodeficiency virus type 1 infection. Journal Infectious Diseases 2001; 184: 699–706
   PubMed Web of Science ®Google Scholar
• Sabri F, De Milito A, Pirskanen R, Elovaara I, Hagberg L, Cinque P, et al. Elevated levels of soluble Fas and Fas ligand in cerebrospinal fluid of patients with AIDS dementia complex. Journal of Neuroimmunology 2001; 114: 197–206
   PubMedGoogle Scholar
• Sacktor N, Haughey N, Cutler R, Tamara A, Turchan J, Pardo C, et al. Novel markers of oxidative stress in actively progressive HIV dementia. Journal of Neuroimmunology 2004; 157: 176–184
   PubMed Web of Science ®Google Scholar
• Sanders VJ, Pittman CA, White MG, Wang G, Wiley CA, Achim CL. Chemokines and receptors in HIV encephalitis. AIDS 1998; 12: 1021–1026
   PubMed Web of Science ®Google Scholar
• Sasseville VG, Smith MM, Mackay CR, Pauley DR, Mansfield KG, Ringler DJ, et al. Chemokine expression in simian immunodeficiency virus-induced AIDS encephalitis. American Journal of Pathology 1996; 149: 1459–1467
   PubMed Web of Science ®Google Scholar
• Schmidtmayerova H, Nottet HS, Nuovo G, Raabe T, Flanagan CR, Dubrovsky L, et al. Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: Implications for recruitment of leukocytes into brain and lymph nodes. Proceedings of the National Academy of Science of the USA 1996; 93: 700–704
   PubMed Web of Science ®Google Scholar
• Scorziello A, Florio T, Bajetto A, Thellung S, Schettini G. TGF-beta1 prevents gp120-induced impairment of Ca2+ homeostasis and rescues cortical neurons from apoptotic death. Journal of Neuroscience Research 1997; 49: 600–607
   PubMed Web of Science ®Google Scholar
• Sevigny JJ, Albert SM, McDermott MP, McArthur JC, Sacktor N, Conant K, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004; 63: 2084–2090
   PubMed Web of Science ®Google Scholar
• Shacklett BL, Cox CA, Wilkens DT, Karl Karlsson R, Nilsson A, Nixon DF, et al. Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection. Journal of Infectious Diseases 2004; 189: 2202–2212
   PubMed Web of Science ®Google Scholar
• Shiramizu B, Gartner S, Williams A, Shikuma C, Ratto-Kim S, Watters M, et al. Circulating proviral HIV DNA and HIV-associated dementia. AIDS 2005; 19: 45–52
   PubMed Web of Science ®Google Scholar
• Shiramizu B, Lau E, Tamamoto A, Uniatowski J, Troelstrup D. Feasibility assessment of cerebrospinal fluid from HIV-1-infected children for HIV proviral DNA and monocyte chemoattractant protein 1 alleles. Journal of Investigative Medicine 2006; 54: 468–472
   PubMed Web of Science ®Google Scholar
• Singer EJ, Syndulko K, Fahy-Chandon B, Schmid P, Conrad A, Tourtellotte WW. Intrathecal IgG synthesis and albumin leakage are increased in subjects with HIV-1 neurologic disease. Journal of Acquired Immune Deficiency Syndrome 1994; 7: 265–271
   PubMed Web of Science ®Google Scholar
• Sozzani S, Introna M, Bernasconi S, Polentarutti N, Cinque P, Poli G, et al. MCP-1 and CCR2 in HIV infection: Regulation of agonist and receptor expression. Journal of Leukoc Biol 1997; 62: 30–33
   PubMed Web of Science ®Google Scholar
• Sporer B, Kastenbauer S, Koedel U, Arendt G, Pfister HW. Increased intrathecal release of soluble fractalkine in HIV-infected patients. AIDS Res Hum Retroviruses 2003; 19: 111–116
   PubMed Web of Science ®Google Scholar
• Sporer B, Koedel U, Goebel FD, Pfister HW. Increased levels of soluble Fas receptor and Fas ligand in the cerebrospinal fluid of HIV-infected patients. AIDS Res Hum Retroviruses 2000; 16: 221–226
   PubMedGoogle Scholar
• Sporer B, Koedel U, Paul R, Eberle J, Arendt G, Pfister HW. Vascular endothelial growth factor (VEGF) is increased in serum, but not in cerebrospinal fluid in HIV associated CNS diseases. Journal of Neurol Neurosurg Psychiatry 2004a; 75: 298–300
   PubMed Web of Science ®Google Scholar
• Sporer B, Missler U, Magerkurth O, Koedel U, Wiesmann M, Pfister HW. Evaluation of CSF glial fibrillary acidic protein (GFAP) as a putative marker for HIV-associated dementia. Infection 2004b; 32: 20–23
   PubMedGoogle Scholar
• Sporer B, Paul R, Koedel U, Grimm R, Wick M, Goebel FD, et al. Presence of matrix metalloproteinase-9 activity in the cerebrospinal fluid of human immunodeficiency virus-infected patients. Journal of Infectious Diseases 1998; 178: 854–857
   PubMed Web of Science ®Google Scholar
• Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67: 227–264
   PubMed Web of Science ®Google Scholar
• Torre D, Zeroli C, Ferraro G, Speranza F, Tambini R, Martegani R, et al. Cerebrospinal fluid levels of IL-6 in patients with acute infections of the central nervous system. Scandinavian Journal of Infectious Diseases 1992; 24: 787–791
   PubMed Web of Science ®Google Scholar
• Towfighi A, Skolasky RL, St Hillaire C, Conant K, McArthur JC. CSF soluble Fas correlates with the severity of HIV-associated dementia. Neurology 2004; 62: 654–656
   PubMedGoogle Scholar
• Tozzi V, Balestra P, Lorenzini P, Bellagamba R, Galgani S, Corpolongo A, et al. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: Results from an urban observational cohort. Journal of Neurovirology 2005; 11: 265–273
   PubMed Web of Science ®Google Scholar
• Tungaturthi PK, Sawaya BE, Singh SP, Tomkowicz B, Ayyavoo V, Khalili K, et al. Role of HIV-1 Vpr in AIDS pathogenesis: Relevance and implications of intravirion, intracellular and free Vpr. Biomed Pharmacother 2003; 57: 20–24
   PubMedGoogle Scholar
• Tyor WR, Glass JD, Griffin JW, Becker PS, McArthur JC, Bezman L, et al. Cytokine expression in the brain during the acquired immunodeficiency syndrome. Annals of Neurology 1992; 31: 349–360
   PubMed Web of Science ®Google Scholar
• Valcour V, Yee P, Williams AE, Shiramizu B, Watters M, Selnes O, et al. Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection - The Hawaii Aging with HIV Cohort. Journal of Neurovirology 2006; 12: 387–391
   PubMed Web of Science ®Google Scholar
• Valle M, Price RW, Nilsson A, Heyes M, Verotta D. CSF quinolinic acid levels are determined by local HIV infection: Cross-sectional analysis and modelling of dynamics following antiretroviral therapy. Brain 2004; 127: 1047–1060
   PubMed Web of Science ®Google Scholar
• von Giesen HJ, Jander S, Koller H, Arendt G. Serum and cerebrospinal fluid levels of interleukin-18 in human immunodeficiency virus type 1-associated central nervous system disease. Journal of Neurovirology 2004; 10: 383–386
   PubMed Web of Science ®Google Scholar
• Vullo V, Mastroianni CM, Lichtner M, Mengoni F, Delia S. Increased cerebrospinal fluid levels of soluble receptors for tumour necrosis factor in HIV-infected patients with neurological diseases. AIDS 1995; 9: 1099–1100
   PubMedGoogle Scholar
• Ware CF, VanArsdale S, VanArsdale TL. Apoptosis mediated by the TNF-related cytokine and receptor families. Journal of Cell Biochem 1996; 60: 47–55
   PubMed Web of Science ®Google Scholar
• Weiss JM, Nath A, Major EO, Berman JW. HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. Journal of Immunology 1999; 163: 2953–2959
   PubMed Web of Science ®Google Scholar
• Wesselingh SL, Glass J, McArthur JC, Griffin JW, Griffin DE. Cytokine dysregulation in HIV-associated neurological disease. Adv Neuroimmunol 1994; 4: 199–206
   PubMedGoogle Scholar
• Westmoreland SV, Rottman JB, Williams KC, Lackner AA, Sasseville VG. Chemokine receptor expression on resident and inflammatory cells in the brain of macaques with simian immunodeficiency virus encephalitis. American Journal of Pathology 1998; 152: 659–665
   PubMed Web of Science ®Google Scholar
• Wojna V, Carlson KA, Luo X, Mayo R, Melendez LM, Kraiselburd E, et al. Proteomic fingerprinting of human immunodeficiency virus type 1-associated dementia from patient monocyte-derived macrophages: A case study. Journal of Neurovirology 2004; 10(Suppl.1)74–81
   PubMedGoogle Scholar
• Zoumpourlis V, Eliopoulos AG, Spandidos DA. Transcriptional activation of the human immunodeficiency virus long terminal repeat sequences by tumor necrosis factor. Anticancer Research 1992; 12: 2065–2068
   PubMed Web of Science ®Google Scholar